What is the appropriate evaluation and management for a patient presenting with fever and thrombocytosis?

Fever with Thrombocytosis: Evaluation and Management

The primary approach is to determine whether thrombocytosis is reactive (secondary to infection, inflammation, or malignancy) or clonal (myeloproliferative neoplasm), as this distinction fundamentally changes management—reactive thrombocytosis requires treating the underlying cause while clonal disease requires hematologic intervention.

Initial Diagnostic Framework

The combination of fever and thrombocytosis most commonly represents reactive thrombocytosis secondary to an infectious or inflammatory process 1, 2. Your immediate priority is identifying the fever source using systematic evaluation per ICU fever guidelines 3:

Source Identification (Based on Clinical Context)

• Collect blood cultures: Obtain at least two sets (60 mL total) from different anatomical sites simultaneously, without time intervals between them 3
• If central venous catheter present: Draw simultaneous peripheral and central cultures to calculate differential time to positivity 3
• Respiratory symptoms: Perform viral nucleic acid amplification testing for respiratory pathogens 3
• Abdominal symptoms or liver function abnormalities: Obtain formal bedside diagnostic ultrasound 3
• Urinary symptoms with pyuria: Replace urinary catheter and culture from newly placed catheter 3

Distinguish Reactive vs. Clonal Thrombocytosis

Reactive thrombocytosis features 2:

• Platelet count typically <1000 × 10⁹/L
• Acute onset coinciding with fever/infection
• Normal or elevated inflammatory markers (CRP, ESR)
• Resolves with treatment of underlying condition

Clonal thrombocytosis features 4:

• Platelet count often >450 × 10⁹/L persistently
• Presence of JAK2, CALR, or MPL mutations (80% of essential thrombocythemia)
• Bone marrow shows increased mature megakaryocytes in loose clusters
• Does not resolve with infection treatment

Specific Etiologies to Consider

Infectious Causes with Reactive Thrombocytosis

1. Dengue fever: Paradoxically causes initial thrombocytopenia followed by severe reactive thrombocytosis during recovery phase 5. Monitor platelet trends; consider short-term aspirin if thrombocytosis is severe (>1000 × 10⁹/L) to prevent thrombotic complications.

2. Severe fever with thrombocytopenia syndrome (SFTS): Presents with fever, initial thrombocytopenia, and leukocenia with gastrointestinal symptoms 6. If suspected based on geographic exposure (China, Japan, Korea), consider favipiravir over ribavirin for viral clearance.

Inflammatory/Vasculitic Causes

Takayasu's arteritis: Prolonged febrile syndrome with reactive thrombocytosis in young women 7. Look for:

• Constitutional symptoms (weight loss, myalgia, arthralgia)
• Vascular symptoms (claudication, blood pressure discrepancies between arms)
• Elevated inflammatory markers
• Requires vascular imaging (CT/MR angiography) for diagnosis

Malignancy-Associated

IL-6 producing tumors (particularly lung cancer): Present with fever, thrombocytosis, hypoalbuminemia, and elevated CRP/fibrinogen 8. If no infectious source identified and constitutional symptoms present, obtain chest imaging and consider malignancy workup.

Management Algorithm

If Reactive Thrombocytosis is Confirmed:

1. Treat underlying infection/inflammation aggressively
2. Thromboprophylaxis: Use standard VTE prophylaxis unless contraindicated
3. Aspirin consideration: Only if platelet count >1000 × 10⁹/L AND no bleeding risk 5
4. Monitor platelet trends: Should normalize within 2-4 weeks of treating underlying cause

If Clonal Thrombocytosis is Suspected:

1. Obtain JAK2V617F, CALR, MPL mutation testing 4
2. Bone marrow biopsy if mutations positive or high clinical suspicion
3. Risk stratification for essential thrombocythemia 4:
   • High risk: History of thrombosis OR age >60 with JAK2 mutation → Requires cytoreductive therapy (hydroxyurea or pegylated interferon-α)
   • Intermediate risk: Age >60 with JAK2 wild-type → Consider cytoreductive therapy
   • Low risk: Age ≤60 with JAK2 mutation → Low-dose aspirin once daily
   • Very low risk: Age ≤60, no thrombosis history, JAK2 wild-type → Low-dose aspirin once daily

If No Source Identified After Initial Workup:

• Measure procalcitonin if bacterial infection probability is low-to-intermediate 3
• Consider PET-CT if transport risk acceptable and other diagnostics unrevealing 3
• Exclude occult malignancy: CT chest/abdomen/pelvis if constitutional symptoms present

Critical Pitfalls to Avoid

1. Do NOT assume thrombocytosis is benign without excluding clonal disorders—essential thrombocythemia carries significant thrombotic risk requiring specific management 4
2. Do NOT give prophylactic platelet transfusions for thrombocytosis—this is contraindicated and may worsen thrombotic risk
3. Do NOT delay cytoreductive therapy in high-risk essential thrombocythemia patients with fever, as infection does not preclude treatment of underlying myeloproliferative neoplasm
4. Do NOT use conventional immunomodulators (steroids, IVIG) empirically for fever with thrombocytosis without specific indication, as these may worsen certain conditions 6